Stockreport
Delcath Announces Accelerated Listing on OTCQB
US:NASDAQ Investor Relations: delcath.com/investors
PDF
NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that after conversations with both Nasdaq and OTC Markets, the Company is able to effect the change in listing to the OTC Markets more quickly than anticipated. The Company's common stock will commence trading on the OTCQB on September 15, 2017 under the symbol "DCTH". About Delcath Systems Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM), and plan
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | DCTH | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
DCTH alerts
DCTH alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting DELCATH SYSTEMS INC COMMON news events
Weekly update
A roundup of the hottest topics
DCTH
NEWS
NEWS
- Delcath Announces Third Quarter Fiscal 2018 Financial Results[GlobeNewswire]
- Delcath files for $100M mixed shelf offering [Seeking Alpha][Seeking Alpha]
- Delcath Announces Enrollment of First Patient in ALIGN Trial[GlobeNewswire]
- CORRECTING and REPLACING – Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma[GlobeNewswire]
- Delcath adds six sites to study of Melphalan/HDS in ocular melanoma; shares ahead 2% [Seeking Alpha][Seeking Alpha]
- More
DCTH
SEC Filings
SEC Filings
- 11/13/18 - Form 10-Q
- 11/9/18 - Form NT
- 11/7/18 - Form 8-K
- DCTH's page on the SEC website
- More